ANG LI to Venous Thromboembolism
This is a "connection" page, showing publications ANG LI has written about Venous Thromboembolism.
Connection Strength
6.851
-
Development and validation of venous thromboembolism-bidirectional encoder representations from transformers (VTE-BERT) natural language processing model. J Thromb Haemost. 2026 07; 24(7):2522-2531.
Score: 0.747
-
Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study. Am J Hematol. 2024 07; 99(7):1230-1239.
Score: 0.683
-
Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy. Am J Hematol. 2023 08; 98(8):1214-1222.
Score: 0.639
-
External validation of the HIGH-2-LOW model: A predictive score for venous thromboembolism after allogeneic transplant. Am J Hematol. 2022 06 01; 97(6):740-748.
Score: 0.591
-
Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol. 2021 09 01; 96(9):1137-1146.
Score: 0.561
-
HIGH-2-LOW risk model to predict venous thromboembolism in allogeneic transplant patients after platelet engraftment. Blood Adv. 2021 01 12; 5(1):167-175.
Score: 0.544
-
Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. J Thromb Haemost. 2019 12; 17(12):2141-2151.
Score: 0.497
-
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Canc Netw. 2019 07 01; 17(7):840-847.
Score: 0.489
-
Review: The quality of evidence is very low for periprocedural bridging in patients receiving VKA for VTE. Ann Intern Med. 2019 06 18; 170(12):JC64.
Score: 0.488
-
Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019 01; 173:158-163.
Score: 0.446
-
Use of Direct Oral Anticoagulants in Special Populations. Hematol Oncol Clin North Am. 2016 10; 30(5):1053-71.
Score: 0.401
-
Factors associated with venous thromboembolism pharmacoprophylaxis initiation in hospitalized medical patients: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 12; 22(12):3521-3531.
Score: 0.175
-
Development and validation of a risk model for hospital-acquired venous thrombosis: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 02; 22(2):503-515.
Score: 0.165
-
Epidemiology of Cancer-Associated Venous Thromboembolism in Patients With Solid and Hematologic Neoplasms in the Veterans Affairs Health Care System. JAMA Netw Open. 2023 06 01; 6(6):e2317945.
Score: 0.161
-
External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol. 2023 04; 201(2):280-284.
Score: 0.156
-
Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017 07; 15(7):1322-1333.
Score: 0.105